Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2021 on February 9, 2022

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX) will release its financial results for Q4 and year-end 2021 on February 9, 2022, after market close. The company will also host a conference call at 4:30 PM ET to discuss these results, along with general corporate updates. Investors can participate via phone or listen to the live webcast on Viking's website. Viking is focused on developing therapies for metabolic disorders, with candidates like VK2809, VK0214, and VK2735 in various stages of clinical trials.

Positive

• Viking's clinical programs include VK2809, which has shown statistically significant reductions in LDL-C and liver fat in Phase 2a trials.
• The company holds exclusive worldwide rights to five therapeutic programs, including VK2809 and VK0214, enhancing its market position.

Negative

• None.

SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2021, after the market close on Wednesday, February 9, 2022.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, February 9, 2022. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until February 16, 2022 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #3676671. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company's third clinical candidate is VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2021-on-february-9-2022-301474192.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics report its financial results for Q4 2021?

Viking Therapeutics will report its financial results on February 9, 2022, after the market close.

What time is the conference call for Viking Therapeutics' financial results?

The conference call will take place at 4:30 PM ET on February 9, 2022.

How can investors participate in Viking Therapeutics' conference call?

Investors can participate by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.

What is VK2809 and what is its current clinical status?

VK2809 is being evaluated in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.

What significant results were achieved in the Phase 2a trial for VK2809?

In the Phase 2a trial, VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared to placebo.